Verastem Inc - ESG Rating & Company Profile powered by AI
Check the end of the page for potential risks for Verastem Inc based on industry, geography and size. Other corporations in the rating industry group for Verastem Inc are shown below. The article contains a questions and answers table about Verastem Inc.
Verastem Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.4; made up of an environmental score of 4.8, social score of 6.4 and governance score of 8.0.
6.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 511 | Wakamoto Pharmaceutical Co Ltd | 6.5 | High |
| 511 | X4 Pharmaceuticals Inc | 6.5 | High |
| 535 | Verastem Inc | 6.4 | High |
| 535 | Al Mansour Pharmaceuticals Industries Co | 6.4 | High |
| 535 | Alpine Immune Sciences Inc | 6.4 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Verastem Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Verastem Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Verastem Inc report the average age of the workforce?
Sign up for free to unlockDoes Verastem Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Verastem Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Verastem Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Verastem Inc offer flexible work?
Sign up for free to unlockDoes Verastem Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Verastem Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Verastem Inc conduct supply chain audits?
Sign up for free to unlockDoes Verastem Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Verastem Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Verastem Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Verastem Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Verastem Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Verastem Inc disclose water use targets?
Sign up for free to unlockDoes Verastem Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Verastem Inc have a product recall in the last two years?
Sign up for free to unlockDoes Verastem Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Verastem Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Verastem Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Verastem Inc disclose parental leave metrics?
Sign up for free to unlockDoes Verastem Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Verastem Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Verastem Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Verastem Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Verastem Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Verastem Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Verastem Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Verastem Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Verastem Inc disclose its waste policy?
Sign up for free to unlockDoes Verastem Inc report according to TCFD requirements?
Sign up for free to unlockDoes Verastem Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Verastem Inc disclose energy use targets?
Sign up for free to unlockDoes Verastem Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Verastem Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Verastem Inc
These potential risks are based on the size, segment and geographies of the company.
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.